Who are Ambisome + Miltefosine's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): liposomal amphotericin B + paromomycin, Liposomal Amphotericin B with Miltefosine.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/ambisome-miltefosine.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

Ambisome + Miltefosine — Competitive Intelligence Brief

Ambisome + Miltefosine (Ambisome + Miltefosine) competitive landscape: 2 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Antifungal/antiparasitic combination. Area: Infectious Disease / Neglected Tropical Diseases.

phase 3 Antifungal/antiparasitic combination Ergosterol (amphotericin B); phosphatidylcholine synthesis pathway (miltefosine) Infectious Disease / Neglected Tropical Diseases Small molecule Live · refreshed every 30 min

Target snapshot

Ambisome + Miltefosine (Ambisome + Miltefosine) — Drugs for Neglected Diseases. Ambisome (liposomal amphotericin B) disrupts fungal cell membranes while miltefosine inhibits phosphatidylcholine synthesis, together providing synergistic antileishmanial and antifungal activity.

Comparator set (2 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
Ambisome + Miltefosine TARGET	Ambisome + Miltefosine	Drugs for Neglected Diseases	phase 3	Antifungal/antiparasitic combination	Ergosterol (amphotericin B); phosphatidylcholine synthesis pathway (miltefosine)
liposomal amphotericin B + paromomycin	liposomal amphotericin B + paromomycin	Drugs for Neglected Diseases	phase 3	Antifungal/antiparasitic combination	Ergosterol (amphotericin B); ribosomal protein synthesis (paromomycin)
Liposomal Amphotericin B with Miltefosine	Liposomal Amphotericin B with Miltefosine	Banaras Hindu University	phase 3	Antifungal/antiparasitic combination	Fungal ergosterol; phosphatidylcholine synthesis pathway

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Antifungal/antiparasitic combination class)

Drugs for Neglected Diseases · 2 drugs in this class
Banaras Hindu University · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Ambisome + Miltefosine — Competitive Intelligence Brief. https://druglandscape.com/ci/ambisome-miltefosine. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab